For Doctors in a Hurry
- Clinicians need to understand how striatal dopamine loss drives functional connectivity changes and motor symptom progression in Parkinson disease.
- The study evaluated 326 patients with Parkinson disease and 29 with REM sleep behavior disorder using MRI and PET imaging.
- Posterior putamen connectivity with posterior cortical regions declined significantly once putaminal dopamine depletion reached approximately 50 percent of normal levels.
- The researchers concluded that corticostriatal connectivity undergoes distinct functional reorganization that correlates with the clinical progression of motor symptoms.
- Monitoring these specific connectivity patterns may eventually help clinicians identify patients at higher risk for accelerated motor deterioration.
Mapping the Functional Consequences of Nigrostriatal Decline
Parkinson disease affects approximately 2% to 3% of the population over age 65 [1]. While diagnosis remains primarily clinical, the underlying pathophysiology involves progressive nigrostriatal degeneration and neuroinflammation, the activation of the brain's innate immune response, which often begins years before motor symptoms manifest [2, 3, 4]. Clinicians currently utilize dopamine transporter imaging to differentiate parkinsonian syndromes from other movement disorders [5]. However, the relationship between dopamine depletion and functional network changes remains poorly understood, complicating efforts to predict the rate of symptomatic progression [6, 4]. A new study of 326 patients now maps how corticostriatal connectivity, the functional communication between the cerebral cortex and the striatum, reorganizes as putaminal dopamine levels decline from 70% to 20% [7]. These findings suggest that specific shifts in brain network signaling may serve as markers for the transition from prodromal to advanced disease stages.
Multimodal Imaging of the Parkinsonian Spectrum
The researchers investigated the neurobiological progression of the disease by recruiting a large cohort of 326 patients with Parkinson disease and 29 patients with idiopathic REM sleep behavior disorder, a condition characterized by the loss of muscle atonia during REM sleep that is often a prodromal stage of alpha-synucleinopathy. To establish a baseline for comparison, the study included two distinct control groups. A total of 40 healthy controls were recruited to determine the extent of striatal dopamine depletion across the Parkinson disease spectrum, while another 40 healthy controls served as a reference for comparing corticostriatal functional connectivity, which is the temporal correlation of neural activity between the cortex and the striatum. Clinical severity was quantified using the Unified Parkinson's Disease Rating Scale, a standardized tool that allows clinicians to track motor and non-motor symptoms and correlate them with objective imaging data.
Biphasic Response in the Posterior Caudate
To track the dynamic evolution of neural networks as neurodegeneration progresses, the researchers employed a sliding window method, a statistical technique that analyzes data in overlapping segments to observe how functional connectivity shifts across a continuous range of dopamine loss. This analysis focused on specific seed regions, which are predefined anatomical areas used to measure the strength of communication with other brain structures, including the anterior and posterior caudate and the putamen on both the more affected and less affected sides of the brain. The findings revealed a distinct biphasic pattern in the more affected side of the posterior caudate, which exhibited elevated functional connectivity with the primary motor cortex and the paracentral lobule, regions essential for voluntary motor execution. This increased communication was present before approximately 50% putaminal dopamine depletion and reached its peak around this 50% depletion level. Clinically, this suggests a compensatory effort by the caudate to maintain motor control during the early stages of nigrostriatal loss. However, this compensatory mechanism appears to have a finite threshold; the researchers observed that the elevated posterior caudate connectivity disappeared when caudate dopamine was abnormally reduced beyond this point, marking a failure of functional reorganization.
Network Failure and Accelerated Motor Decline
The study identified a distinct divergence in how different striatal regions communicate with the cortex as dopamine levels fall. While the functional connectivity between the posterior caudate and primary motor cortex was elevated from the prodromal to early stages of Parkinson disease, the posterior putamen exhibited a markedly different profile. Specifically, the functional connectivity between the posterior putamen and motor cortex remained unchanged throughout the entire progression of the disease. During the period of elevated caudate-motor connectivity, motor symptom progression remained relatively slow, suggesting that the posterior caudate may temporarily buffer the effects of dopamine loss through these cortical reinforcements. As the disease progresses, the failure of specific networks in the putamen appears to drive clinical worsening. The researchers observed that the connectivity between the posterior putamen and posterior cortical regions, including the superior parietal cortex, precuneus, and cuneus, declined from the onset of motor symptoms. This specific reduction in posterior putamen connectivity occurred when putaminal dopamine depletion reached approximately 50%, a critical physiological tipping point. The study found that motor symptoms deteriorated linearly after putaminal dopamine depletion reached the 50% threshold, indicating that the transition to rapid clinical decline is tied to the failure of posterior putaminal networks rather than a uniform loss of dopamine across the entire striatum.
References
1. Corica F, Feo MSD, Gorica J, et al. PET Imaging of Neuro-Inflammation with Tracers Targeting the Translocator Protein (TSPO), a Systematic Review: From Bench to Bedside. Diagnostics. 2023. doi:10.3390/diagnostics13061029
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of Neurology Neurosurgery & Psychiatry. 2008. doi:10.1136/jnnp.2007.131045
3. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01486-5
4. Xu D, Yong C, Xu Y, Chen-Yu S, Peng L. Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01353-3
5. Mercer MK, Revels JW, Blacklock LC, et al. Practical Overview of 123I-Ioflupane Imaging in Parkinsonian Syndromes.. Radiographics : a review publication of the Radiological Society of North America, Inc. 2024. doi:10.1148/rg.230133
6. Sivanandy P, Leey TC, Xiang TC, et al. Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms. International Journal of Environmental Research and Public Health. 2021. doi:10.3390/ijerph19010364
7. Yoo HS, Kim H, Park M, et al. Functional Reorganization of Corticostriatal Connectivity Across the Degree of Nigrostriatal Degeneration in Parkinson Disease.. Neurology. 2026. doi:10.1212/WNL.0000000000214812
